ChrysCapital’s plan to exit Eris Lifesciences through an IPO comes at a time when public markets have shown a strong appetite for IPOs of pharma and healthcare firms. In December, Mint reported that ChrysCapital was planning to exit its five-year-old investment in Eris for around Rs.600-650 crore. “ChrysCapital has started discussions with several investment banks for an IPO of Eris Lifesciences. Emails sent on Monday to Amit Bakshi, founder and managing director of Eris Lifesciences, and Kunal Shroff, managing director at ChrysCapital, did not elicit any response. ChrysCapital’s plan to exit Eris Lifesciences through an IPO comes at a time when public markets have shown a strong appetite for IPOs of pharma and healthcare firms.

Source: Mint August 23, 2016 19:30 UTC